Cardio Diagnostics Holdings (CDIO) Revenue (2022 - 2026)
Cardio Diagnostics Holdings (CDIO) posted Revenue of $2680.0 for Q1 2026, down 24.61% sequentially from $3555.0 in Q4 2025, and up 185.11% YoY from $940.0 in Q1 2025.
Cardio Diagnostics Holdings (CDIO) Revenue (2022 - 2026) Analysis & Trends
Cardio Diagnostics Holdings has reported Revenue for 5 years, with the latest figure at $2680.0 in Q1 2026.
- Quarterly Revenue rose 185.11% year-over-year to $2680.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16565.0 (down 16.77% YoY) and the FY2025 annual result came in at $14825.0, down 57.51% from the prior year.
- Revenue eased to $2680.0 in Q1 2026 per CDIO's latest filing, from $3555.0 in the prior quarter.
- Over five years, Revenue peaked at $15928.0 in Q1 2024 and troughed at $940.0 in Q1 2025.
- A 5-year average of $5416.2 and a median of $4512.0 in 2024 frame the typical range for Revenue.
- The sharpest annual moves came in 2023 and 2025: Revenue surged 458.95% in 2023, then tumbled 94.1% in 2025.
- Over 5 years, Revenue stood at $950.0 in 2022, then soared by 458.95% to $5310.0 in 2023, then decreased by 15.03% to $4512.0 in 2024, then fell by 21.21% to $3555.0 in 2025, then declined by 24.61% to $2680.0 in 2026.
- According to Business Quant data, Revenue over the past three periods registered $2680.0, $3555.0, and $2855.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 145.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.71 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.29 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 425.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 674.14 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 1.06 Bn |
| 10 | Cardio Diagnostics Holdings | 6.42 Mn | 835,350.96 | - | 5,360.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5,360.00 |
| Mar 31, 2026 | 2,680.00 |
| Dec 31, 2025 | 3,555.00 |
| Sep 30, 2025 | 2,855.00 |
| Jun 30, 2025 | 7,475.00 |
| Mar 31, 2025 | 940.00 |
| Dec 31, 2024 | 4,512.00 |
| Sep 30, 2024 | 6,580.00 |
| Jun 30, 2024 | 7,870.00 |
| Mar 31, 2024 | 15,928.00 |
| Dec 31, 2023 | 5,310.00 |
| Sep 30, 2023 | 10,030.00 |
| Jun 30, 2023 | 1,725.00 |
| Dec 31, 2022 | 950.00 |